ProMetic Life Sciences Inc. (TSE:PLI)‘s stock had its “speculative buy” rating reissued by investment analysts at TD Securities in a research report issued to clients and investors on Wednesday. They currently have a C$4.50 price target on the stock. TD Securities’ price objective suggests a potential upside of 84.43% from the company’s previous close.

Several other equities research analysts have also issued reports on PLI. Scotiabank reaffirmed an “outperform” rating and issued a C$5.00 price objective on shares of ProMetic Life Sciences in a research note on Wednesday, August 10th. Royal Bank Of Canada reaffirmed an “outperform” rating on shares of ProMetic Life Sciences in a research note on Thursday, August 25th. CIBC reduced their price objective on shares of ProMetic Life Sciences from C$5.00 to C$4.85 in a research note on Thursday, August 25th. Finally, Bloom Burton reaffirmed a “hold” rating on shares of ProMetic Life Sciences in a research note on Thursday, October 13th. Two research analysts have rated the stock with a hold rating and seven have given a buy rating to the company’s stock. The stock presently has an average rating of “Buy” and a consensus price target of C$4.84.

Analyst Recommendations for ProMetic Life Sciences (TSE:PLI)

ProMetic Life Sciences (TSE:PLI) opened at 2.44 on Wednesday. The company’s market cap is $1.51 billion. The stock’s 50 day moving average is $2.84 and its 200 day moving average is $2.92. ProMetic Life Sciences has a 12 month low of $1.88 and a 12 month high of $3.62.

ILLEGAL ACTIVITY NOTICE: This report was originally posted by The Cerbat Gem and is the sole property of of The Cerbat Gem. If you are reading this report on another website, it was illegally stolen and republished in violation of international trademark and copyright legislation. The correct version of this report can be viewed at https://www.thecerbatgem.com/2016/11/25/prometic-life-sciences-inc-pli-rating-reiterated-by-td-securities.html.

ProMetic Life Sciences Company Profile

ProMetic Life Sciences Inc (ProMetic) is a Canada-based biopharmaceutical company. The Company has two segments: Small Molecule Therapeutics and Protein Technology. The Company offers its technology platform for large-scale drug purification of biologics, drug development, proteomics and the elimination of pathogens to various industries, and uses its own affinity technology that provides for extraction and purification of therapeutic proteins from human plasma in order to develop therapeutics and orphan drugs.

Receive News & Stock Ratings for ProMetic Life Sciences Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for ProMetic Life Sciences Inc. and related stocks with our FREE daily email newsletter.